Exploring the full spectrum of macrophage activation

Nature Reviews Immunology

Volumn 8, Issue 12, 2008, Pages 958-969

  Mosser, David M ^a   Edwards, Justin P ^a  

^a Bldg 142   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; INTERLEUKIN 13; INTERLEUKIN 4;

ADAPTIVE IMMUNITY; BONE MARROW; CELL ACTIVATION; CELL ACTIVITY; CELL HETEROGENEITY; CELL POPULATION; CELL SECRETION; DISEASE ASSOCIATION; HELPER CELL; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MACROPHAGE ACTIVATION; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; OBESITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; WOUND HEALING;

ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGE ACTIVATION; MACROPHAGES; WOUND HEALING;

EID: 56749174940     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2448     Document Type: Review

References (119)

1. Nathan, C. Metchnikoff's legacy in 2008. Nature Immunol. 9, 695-698 (2008).
2. Kono, H. & Rock, K. L. How dying cells alert the immune system to danger. Nature Rev. Immunol. 8, 279-289 (2008).
3. Erwig, L. P. & Henson, P. M. Immunological consequences of apoptotic cell phagocytosis. Am. J. Pathol. 171, 2-8 (2007).
4. Zhang, X. & Mosser, D. M. Macrophage activation by endogenous danger signals. J. Pathol. 214, 161-178 (2008).
5. Chen, C. J. et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nature Med. 13, 851-856 (2007).
6. Park, J. S. et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370-7377 (2004).
7. Mackaness, G. B. Cellular immunity and the parasite. Adv. Exp. Med. Biol. 93, 65-73 (1977).
8. Gordon, S. Alternative activation of macrophages. Nature Rev. Immunol. 3, 23-35 (2003).
9. Martinez, F. O., Sica, A., Mantovani, A. & Locati, M. Macrophage activation and polarization. Front. Biosci. 13, 453-461 (2008). In this paper the authors proposed that the M1 and M2 designation for macrophages should be primarily based on the ratio of IL-12 to IL-10 production.
10. Edwards, J. P., Zhang, X., Frauwirth, K. A. & Mosser, D. M. Biochemical and functional characterization of three activated macrophage populations. J. Leukoc. Biol. 80, 1298-1307 (2006). This work shows that alternatively activated macrophages are biochemically and functionally distinct from regulatory macrophages.
11. Gordon, S. & Taylor, P. R. Monocyte and macrophage heterogeneity. Nature Rev. Immunol. 5, 953-964 (2005).
12. Nahrendorf, M. et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 204, 3037-3047 (2007).
13. Sunderkotter, C. et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J. Immunol. 172, 4410-4417 (2004).
14. Geissmann, F., Jung, S. & Littman, D. R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19, 71-82 (2003). This study shows that distinct monocyte populations exist, and have different cell-surface markers and homing capacities.
15. Strauss-Ayali, D., Conrad, S. M. & Mosser, D. M. Monocyte subpopulations and their differentiation patterns during infection. J. Leukoc. Biol. 82, 244-252 (2007).
16. Passlick, B., Flieger, D. & Ziegler-Heitbrock, H. W. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood 74, 2527-2534 (1989).
17. Randolph, G. J., Inaba, K., Robbiani, D. F., Steinman, R. M. & Muller, W. A. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 11, 753-761 (1999).
18. Auffray, C. et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317, 666-670 (2007).
19. Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nature Neurosci. 10, 1538-1543 (2007).
20. Gordon, S. The macrophage: past, present and future. Eur. J. Immunol. 37, S9-S17 (2007).
21. O'Shea, J. J. & Murray, P. J. Cytokine signaling modules in inflammatory responses. Immunity 28, 477-487 (2008).
22. Dale, D. C., Boxer, L. & Liles, W. C. The phagocytes: neutrophils and monocytes. Blood 112, 935-945 (2008).
23. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301, 640-643 (2003). This work shows that mice lacking the TLR adaptor molecule TRIF are defective in TLR3- and TLR4-mediated IFNγ production.
24. Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005).
25. Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M. & Stockinger, B. TGF? in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006).
26. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
27. Kolls, J. K. & Linden, A. Interleukin-17 family members and inflammation. Immunity 21, 467-476 (2004).
28. Fadok, V. A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890-898 (1998). This work shows that the phagocytosis of apoptotic cells by macrophages is associated with the production of TGFβ, which inhibits the production of pro-inflammatory cytokines.
29. Filipe-Santos, O. et al. Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18, 347-361 (2006).
30. Nandan, D. & Reiner, N. E. Attenuation of γ interferoninduced tyrosine phosphorylation in mononuclear phagocytes infected with Leishmania donovani: selective inhibition of signaling through Janus kinases and Stat1. Infect. Immun. 63, 4495-4500 (1995).
31. Pai, R. K., Convery, M., Hamilton, T. A., Boom, W. H. & Harding, C. V. Inhibition of IFN-γ-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J. Immunol. 171, 175-184 (2003).
32. Szekanecz, Z. & Koch, A. E. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 19, 289-295 (2007).
33. + T cells to be sustained during chronic infection. J. Immunol. 179, 3926-3936 (2007). This study shows that the production of IL-4 and IL-13 is a rapid innate immune response to tissue injury.
34. Brandt, E., Woerly, G., Younes, A. B., Loiseau, S. & Capron, M. IL-4 production by human polymorphonuclear neutrophils. J. Leukoc. Biol. 68, 125-130 (2000).
35. Reese, T. A. et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 447, 92-96 (2007). This work demonstrates that chitin induces the production of IL-4 by eosinophils and basophils.
36. Kreider, T., Anthony, R. M., Urban, J. F. Jr & Gause, W. C. Alternatively activated macrophages in helminth infections. Curr. Opin. Immunol. 19, 448-453 (2007).
37. Stein, M., Keshav, S., Harris, N. & Gordon, S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176, 287-292 (1992). This is the initial observation that IL-4 upregulates the expression of macrophage mannose receptor, thereby giving rise to the term alternative activation.
38. Raes, G., Beschin, A., Ghassabeh, G. H. & De, B. P. Alternatively activated macrophages in protozoan infections. Curr. Opin. Immunol. 19, 454-459 (2007).
39. Wilson, M. S. et al. Immunopathology of schistosomiasis. Immunol. Cell Biol. 85, 148-154 (2007).
40. Cordeiro-da-Silva, A. et al. Immunological alterations induced by polyamine derivatives on murine splenocytes and human mononuclear cells. Int. Immunopharmacol. 4, 547-556 (2004).
41. H2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nature Med. 12, 955-960 (2006).
42. Zhao, A. et al. Th2 cytokine-induced alterations in intestinal smooth muscle function depend on alternatively activated macrophages. Gastroenterology 135, 217-225 (2008).
43. Raes, G. et al. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J. Leukoc. Biol. 71, 597-602 (2002).
44. Kzhyshkowska, J. et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 107, 3221-3228 (2006).
45. Zhu, Z. et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 304, 1678-1682 (2004).
46. Bleau, G., Massicotte, F., Merlen, Y. & Boisvert, C. Mammalian chitinase-like proteins. EXS 87, 211-221 (1999).
47. Fusetti, F. et al. Structure of human chitotriosidase. Implications for specific inhibitor design and function of mammalian chitinase-like lectins. J. Biol. Chem. 277, 25537-25544 (2002).
48. H2-type cytokines and inversely correlates with nitric oxide production.
49. Munitz, A., Brandt, E. B., Mingler, M., Finkelman, F. D. & Rothenberg, M. E. Distinct roles for IL-13 and IL-4 via IL-13 receptor α1 and the type II IL-4 receptor in asthma pathogenesis. Proc. Natl Acad. Sci. USA 105, 7240-7245 (2008).
50. Harris, J. et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 27, 505-517 (2007).
51. Kropf, P. et al. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. FASEB J. 19, 1000-1002 (2005).
52. Muller, U. et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179, 5367-5377 (2007).
53. Shirey, K. A., Cole, L. E., Keegan, A. D. & Vogel, S. N. Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. J. Immunol. 181, 4159-4167 (2008).
54. Tumitan, A. R., Monnazzi, L. G., Ghiraldi, F. R., Cilli, E. M. & hado de Medeiros, B. M. Pattern of macrophage activation in Yersinia-resistant and Yersinia-susceptible strains of mice. Microbiol. Immunol. 51, 1021-1028 (2007).
55. Sternberg, E. M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nature Rev. Immunol. 6, 318-328 (2006).
56. Elenkov, I. J. Glucocorticoids and the Th1/Th2 balance. Ann. N. Y. Acad. Sci. 1024, 138-146 (2004).
57. Liu, Y. et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J. Immunol. 162, 3639-3646 (1999).
58. Franchimont, D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann. NY Acad. Sci. 1024, 124-137 (2004).
59. Mosser, D. M. The many faces of macrophage activation. J. Leukoc. Biol. 73, 209-212 (2003).
60. Lucas, M., Zhang, X., Prasanna, V. & Mosser, D. M. ERK activation following macrophage FcγR ligation leads to chromatin modifications at the IL-10 locus. J. Immunol. 175, 469-477 (2005). This paper shows that activation of ERK is required for the hypersecretion of IL-10 by regulatory macrophages.
61. Gerber, J. S. & Mosser, D. M. Reversing lipopolysaccharide toxicity by ligating the macrophage Fcγ receptors. J. Immunol. 166, 6861-6868 (2001).
62. Strassmann, G., Patil-Koota, V., Finkelman, F., Fong, M. & Kambayashi, T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J. Exp. Med. 180, 2365-2370 (1994).
63. Hasko, G., Pacher, P., Deitch, E. A. & Vizi, E. S. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol. Ther. 113, 264-275 (2007).
64. Hasko, G., Szabo, C., Nemeth, Z. H. & Deitch, E. A. Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a β-adrenoceptor-mediated mechanism. J. Neuroimmunol. 122, 34-39 (2002).
65. Sirois, J., Menard, G., Moses, A. S. & Bissonnette, E. Y. Importance of histamine in the cytokine network in the lung through H2 and H3 receptors: stimulation of IL-10 production. J. Immunol. 164, 2964-2970 (2000).
66. Weigert, A. et al. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol. Biol. Cell 18, 3810-3819 (2007).
67. Lam, C. W., Perretti, M. & Getting, S. J. Melanocortin receptor signaling in RAW264.7 macrophage cell line. Peptides 27, 404-412 (2006).
68. Delgado, M., Munoz-Elias, E. J., Gomariz, R. P. & Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162, 1707-1716 (1999).
69. Huang, H., Park, P. H., McMullen, M. R. & Nagy, L. E. Mechanisms for the anti-inflammatory effects of adiponectin in macrophages. J. Gastroenterol. Hepatol. 1, S50-S53 (2008).
70. Ando, M., Tu, W., Nishijima, K. & Iijima, S. Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem. Biophys. Res. Commun. 369, 878-883 (2008).
71. Biswas, S. K. et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation). Blood 107, 2112-2122 (2006). In this study, tumour-associated macrophages are profiled by microarray analysis.
72. Miles, S. A., Conrad, S. M., Alves, R. G., Jeronimo, S. M. & Mosser, D. M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J. Exp. Med. 201, 747-754 (2005).
73. Baetselier, P. D. et al. Alternative versus classical macrophage activation during experimental African trypanosomosis. Int. J. Parasitol. 31, 575-587 (2001).
74. Kim, C. et al. Antiinflammatory cAMP signaling and cell migration genes co-opted by the anthrax bacillus. Proc. Natl Acad. Sci. USA 105, 6150-6155 (2008).
75. Agrawal, A. & Pulendran, B. Anthrax lethal toxin: a weapon of multisystem destruction. Cell Mol. Life Sci. 61, 2859-2865 (2004).
76. Benoit, M., Barbarat, B., Bernard, A., Olive, D. & Mege, J. L. Coxiella burnetii, the agent of Q fever, stimulates an atypical M2 activation program in human macrophages. Eur. J. Immunol. 38, 1065-1070 (2008).
77. Mahalingam, S. & Lidbury, B. A. Suppression of lipopolysaccharide- induced antiviral transcription factor (STAT-1 and NF-κB) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc. Natl Acad. Sci. USA 99, 13819-13824 (2002).
78. Stout, R. D. et al. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J. Immunol. 175, 342-349 (2005).
79. Klimp, A. H., de Vries, E. G., Scherphof, G. L. & Daemen, T. A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 44, 143-161 (2002).
80. Teng, M. W., Swann, J. B., Koebel, C. M., Schreiber, R. D. & Smyth, M. J. Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84, 988-993 (2008).
81. Lin, E. Y. & Pollard, J. W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67, 5064-5066 (2007). This work correlates macrophage recruitment into tumours with an angiogenic switch and a poor prognosis.
82. Swann, J. B. et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl Acad. Sci. USA 105, 652-656 (2008).
83. Romieu-Mourez, R. et al. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. Cancer Res. 66, 10576-10585 (2006).
84. Pollard, J. W. Macrophages define the invasive microenvironment in breast cancer. J. Leukoc. Biol. 84, 623-630 (2008).
85. Liu, C. H. et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276, 18563-18569 (2001).
86. Knowles, H. J. & Harris, A. L. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res. 3, 318-322 (2001).
87. Kuang, D. M. et al. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 110, 587-595 (2007).
88. de Visser, K. E., Korets, L. V. & Coussens, L. M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005).
89. Hagemann, T. et al. "Re-educating" tumor-associated macrophages by targeting NF-κB. J. Exp. Med. 205, 1261-1268 (2008).
90. Lin, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246 (2006).
91. Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175-184 (2007).
92. Straus, D. S. & Glass, C. K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28, 551-558 (2007).
93. Heilbronn, L. K. & Campbell, L. V. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14, 1225-1230 (2008).
94. Zeyda, M. & Stulnig, T. M. Adipose tissue macrophages. Immunol. Lett. 112, 61-67 (2007).
95. Cinti, S. et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46, 2347-2355 (2005).
96. Bastard, J. P. et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17, 4-12 (2006).
97. Hansson, G. K., Robertson, A. K. & Soderberg-Naucler, C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 1, 297-329 (2006).
98. Fernandez, A. Z. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. PPAR Res. 2008, 285842 (2008).
99. Martin-Fuentes, P. et al. Individual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory response. J. Immunol. 179, 3242-3248 (2007).
100. Haque, S., Mirjafari, H. & Bruce, I. N. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr. Opin. Lipidol. 19, 338-343 (2008).
101. Roark, C. L., Simonian, P. L., Fontenot, A. P., Born, W. K. & O'Brien, R. L. γδ T cells: an important source of IL-17. Curr. Opin. Immunol. 20, 353-357 (2008).
102. H17 lineage. Nature 441, 231-234 (2006).
103. costa-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A. & Sallusto, F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunol. 8, 942-949 (2007).
104. Denning, T. L., Wang, Y. C., Patel, S. R., Williams, I. R. & Pulendran, B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nature Immunol. 8, 1086-1094 (2007).
105. Jovanovic, D. V. et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J. Immunol. 160, 3513-3521 (1998).
106. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682 (2006).
107. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev. Immunol. 3, 133-146 (2003).
108. MacMicking, J., Xie, Q. W. & Nathan, C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15, 323-350 (1997).
109. Martinez, F. O., Gordon, S., Locati, M. & Mantovani, A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177, 7303-7311 (2006).
110. Kodelja, V. et al. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 α with a Th2-associated expression pattern. J. Immunol. 160, 1411-1418 (1998).
111. Raes, G. et al. FIZZ1 and Ym as tools to discriminate between differentially activated macrophages. Dev. Immunol. 9, 151-159 (2002).
112. Wirnsberger, G., Hebenstreit, D., Posselt, G., Horejs-Hoeck, J. & Duschl, A. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur. J. Immunol. 36, 1882-1891 (2006).
113. Ruckerl, D., Hessmann, M., Yoshimoto, T., Ehlers, S. & Holscher, C. Alternatively activated macrophages express the IL-27 receptor ? chain WSX-1. Immunobiology 211, 427-436 (2006).
114. Wynes, M. W. & Riches, D. W. Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J. Immunol. 171, 3550-3559 (2003).
115. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002).
116. Goerdt, S. & Orfanos, C. E. Other functions, other genes: alternative activation of antigen presenting cells. Immunity 10, 137-142 (1999).
117. Torocsik, D., Bardos, H., Nagy, L. & Adany, R. Identification of factor XIII-A as a marker of alternative macrophage activation. Cell. Mol. Life Sci. 62, 2132-2139 (2005).
118. Sironi, M. et al. Differential regulation of chemokine production by Fcγ receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J. Leukoc. Biol. 80, 342-349 (2006).
119. Stumhofer, J. S. & Hunter, C. A. Advances in understanding the anti-inflammatory properties of IL-27. Immunol. Lett. 117, 123-130 (2008).